Saturday 17 October 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 331.8% and free cash flow fell 7.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.30
1.34
−6.19%
Follow MLYS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(42.14%) | (36.91%) | (30.98%) | (80.88%) | |
| (39.48%) | (35.65%) | (30.12%) | (69.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(29.74%) | (23.93%) | (23.80%) | (54.07%) | |
Free Cash Flow per Share |
(2.43) | (2.11) | (1.65) | (1.64) | |
Free Cash Flow |
(171.37) | (142.47) | (136.40) | (138.79) | |
Capital Expenditures |
— | (0.05) | — | — | |
| Other line items | |||||
Cash ROIC |
(14.65%) | (10.93%) | (10.62%) | (10.59%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.00 | 0.92 | 0.90 | 0.40 | |
Depreciation/Fixed assets |
8.71 | 1.55 | 1.56 | 6.11 | |
Capex/Depreciation |
0.00 | (0.88) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.43) | (2.10) | (1.65) | (1.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates